In prostate cancer, A10 2′-fluoropyrimidine RNA aptamer binding to prostate-specific membrane antigen (PSMA) has been widely applied as the targeting ligands for targeted nanoparticles [11]. The gene discussed is FOLH1; the disease is prostate carcinoma.